Home›Stocks›JNJ

JNJ — structural market context

Johnson & Johnson

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

JNJ short interest & days to cover

As of 2026-10-30 (FINRA settlement date)

SHARES SHORT
17.1M
% OF FLOAT
0.7%
DAYS TO COVER
2.4
CHANGE VS PRIOR
+1.8%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float.

How short interest and days to cover are measured →

JNJ fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-10-29 · 24d2K$271.04
2026-10-28 · 25d133$268.73
2026-10-27 · 26d145$266.3

SEC fails-to-deliver files, published twice a month in half-month batches and with a delay; each row carries its settlement date and age.

How fails-to-deliver are reported →

What changed

As of the close on Nov 20. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 19 close to the Nov 20 close: +1.25%.

Volume

1.58× its 20-session average on Nov 20.

Includes pre- and post-market trading.

Short interest

Short interest 17.1M shares (settlement Oct 30) vs 16.8M (Oct 15).

No new file loaded in this window. Latest file: settlement Oct 30, loaded Nov 11.

Fails-to-deliver

Latest file (settlements Oct 15–Oct 30, published Nov 17): 10 days with fails, largest 5K shares on Oct 26.

Previous file (settlements Oct 1–Oct 14, published Nov 3): 5 days with fails, largest 2K shares on Oct 5.

No new file loaded in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

JNJ: what the public data shows

Each row is the latest public record we hold for JNJ, with its own date and source. Figures are descriptive and delayed by their source.

DataLatest recordAs ofSource
Short interest→ Short Interest & FTD tracker17.1M shares short · 2.4 days to cover · 0.7% of float · +1.8% vs 2026-10-152026-10-30FINRA
Fails-to-deliver→ Short Interest & FTD tracker2K shares failed to deliver on 2026-10-292026-10-29SEC fails-to-deliver files
Insider Form 4 (P/S)→ Insider Buying tracker0 purchases and 5 sales in 12 months · latest filed 2026-11-13 by Forminard Elizabeth2026-11-13SEC Form 4
Offering filings1 filing in 12 months · latest S-3ASR on 2026-02-112026-02-11SEC EDGAR
Analyst rating actions5 recent actions · latest published by Johnson Rice on 2026-10-212026-10-21Firms' published actions
Short interest→ Short Interest & FTD tracker
Latest record
17.1M shares short · 2.4 days to cover · 0.7% of float · +1.8% vs 2026-10-15
As of
2026-10-30
Source
FINRA
Fails-to-deliver→ Short Interest & FTD tracker
Latest record
2K shares failed to deliver on 2026-10-29
As of
2026-10-29
Source
SEC fails-to-deliver files
Insider Form 4 (P/S)→ Insider Buying tracker
Latest record
0 purchases and 5 sales in 12 months · latest filed 2026-11-13 by Forminard Elizabeth
As of
2026-11-13
Source
SEC Form 4
Offering filings
Latest record
1 filing in 12 months · latest S-3ASR on 2026-02-11
As of
2026-02-11
Source
SEC EDGAR
Analyst rating actions
Latest record
5 recent actions · latest published by Johnson Rice on 2026-10-21
As of
2026-10-21
Source
Firms' published actions

JNJ events and their magnitude

Latest SEC filing in the event study

Form 4 · other · filed 2026-11-13 · View on sec.gov ↗

…

How the Event Study works →

JNJ insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 5 sales

Most recent Form 4 shown for JNJ: Forminard Elizabeth (EVP, Chief Legal Officer) reported a sale (code S) of 13,072 shares at $284.39 on 2026-11-12, filed 2026-11-13 (1 day after the trade).

InsiderTypeSharesPriceValueTrade dateFiled
Forminard Elizabeth · officer: EVP, Chief Legal OfficerSale (S)13K$284.39$3.7M2026-11-122026-11-13 · +1d
Schmid Timothy · officer: EVP, WW Chair, MedTechSale (S)23K$274.74$6.2M2026-09-022026-09-04 · +2d
Taubert Jennifer L · officer: EVP, WWC. Innovative MedicineSale (S)15K$263.36$4.0M2026-08-172026-08-18 · +1d
Duato Joaquin · director, officer: CEO and Chairman of the BoardSale (S)21K$262.00$5.5M2026-08-132026-08-14 · +1d
Duato Joaquin · director, officer: CEO and Chairman of the BoardSale (S)102K$261.00$26.7M2026-08-132026-08-14 · +1d

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

JNJ offering filings (SEC)

1 SEC filing in the last 12 months, none in the last 90 days. The most recent: Automatic shelf registration statement (Form S-3ASR) S-3ASR, filed 2026-02-11. View on sec.gov ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Offering registration and prospectus filings (S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5) on SEC EDGAR in the last 12 months, each counted once.

SEC offering filings explained →

JNJ analyst ratings

FirmActionRatingPublished
Johnson RicedowngradeHold (from Buy)2026-10-21
Evercore ISIprice_target—2026-10-20
Cowen & Co.holdBuy2026-10-20
Wells Fargoprice_target—2026-10-16
Bernsteinprice_target—2026-10-15

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is JNJ's short interest?
As of the FINRA settlement date 2026-10-30, JNJ had 17.1M shares sold short — 0.7% of its float, with 2.4 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying JNJ?
In the last 12 months of SEC Form 4 filings, JNJ recorded 0 insider purchases and 5 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What are the SEC offering filings listed for JNJ?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 12 months the issuer of JNJ filed 1; the most recent was a automatic shelf registration statement (Form S-3ASR) on 2026-02-11. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
What do analysts say about JNJ?
The most recent action: Johnson Rice downgrade to Hold on 2026-10-21. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell JNJ?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

Other companies in the same SEC industry: Pharmaceutical Preparations

ACTU · Actuate Therapeutics, Inc.HELP · Helus Pharma Inc.PMN · ProMIS Neurosciences Inc.VRDN · Viridian Therapeutics, Inc. CoABBV · ABBVIE INC.ABEO · Abeona Therapeutics Inc.

Industry: SIC code 2834 as recorded on SEC EDGAR.

All tickers starting with J →

JNJ: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.

Sign up with Google or emailCreate a free account

Trading futures and options involves substantial risk of loss and is not suitable for every investor. Past performance is not necessarily indicative of future results. TradeAI News provides market data and context for information only and is not investment advice. Full risk disclosure: tradeainews.com/risk-disclosures

Hypothetical Performance Disclosure. Hypothetical performance results have many inherent limitations, some of which are described below.

Read the full disclosure

No representation is being made that any account will or is likely to achieve profits or losses similar to those shown; in fact, there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. for example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. There are numerous other factors related to the markets in general or to the implementation of any specific trading program which cannot be fully accounted for in the preparation of hypothetical performance results and all which can adversely affect trading results.

TradeAI News does not publish trading performance, real or hypothetical, for any account or strategy. Price-movement figures in the product are observations of price, not results of a trading program.

We use cookies to measure how visitors find and use this site (Google Analytics, Microsoft Clarity and our own cookies). Nothing non-essential loads until you choose. Privacy Policy